Hunan Jiudian Pharmaceutical Co Ltd Net Assets
Hunan Jiudian Pharmaceutical Co Ltd net assets. Based on the latest financial reports, Hunan Jiudian Pharmaceutical Co Ltd (300705) has net assets worth CN¥2.75 Billion CNY (≈ $402.09 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.18 Billion ≈ $611.39 Million USD) and total liabilities (CN¥1.43 Billion ≈ $209.30 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Hunan Jiudian Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.75 Billion |
| % of Total Assets | 65.77% |
| Annual Growth Rate | 25.89% |
| 5-Year Change | 153.45% |
| 10-Year Change | 761.47% |
| Growth Volatility | 25.18 |
Net Assets of Hunan Jiudian Pharmaceutical Co Ltd (2013–2025)
Net assets of Hunan Jiudian Pharmaceutical Co Ltd from 2013 to 2025. This chart illustrates how Hunan Jiudian Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See 300705 net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Hunan Jiudian Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual net assets of Hunan Jiudian Pharmaceutical Co Ltd from 2013 to 2025. For live market cap and overall valuation, see 300705 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.79 Billion ≈ $407.71 Million |
+10.27% |
| 2024-12-31 | CN¥2.53 Billion ≈ $369.74 Million |
+28.05% |
| 2023-12-31 | CN¥1.97 Billion ≈ $288.75 Million |
+27.09% |
| 2022-12-31 | CN¥1.55 Billion ≈ $227.20 Million |
+41.23% |
| 2021-12-31 | CN¥1.10 Billion ≈ $160.87 Million |
+31.55% |
| 2020-12-31 | CN¥835.68 Million ≈ $122.29 Million |
+9.69% |
| 2019-12-31 | CN¥761.87 Million ≈ $111.49 Million |
+6.09% |
| 2018-12-31 | CN¥718.16 Million ≈ $105.09 Million |
+8.77% |
| 2017-12-31 | CN¥660.26 Million ≈ $96.62 Million |
+104.14% |
| 2016-12-31 | CN¥323.43 Million ≈ $47.33 Million |
+27.08% |
| 2015-12-31 | CN¥254.51 Million ≈ $37.24 Million |
+21.27% |
| 2014-12-31 | CN¥209.87 Million ≈ $30.71 Million |
+19.34% |
| 2013-12-31 | CN¥175.85 Million ≈ $25.73 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hunan Jiudian Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1831.6% over the analyzed period, indicating profitable operations and earnings retention.
Hunan Jiudian Pharmaceutical Co Ltd Net Assets Breakdown (December 2025)
Hunan Jiudian Pharmaceutical Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.53 Billion | 57.62% |
| Other Components | CN¥1.13 Billion | 42.38% |
| Total Equity | CN¥2.66 Billion | 100.00% |
Hunan Jiudian Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Hunan Jiudian Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SGSG Science&technology Co Ltd Zhuhai
SHE:300561
|
$769.64 Million |
|
Hangzhou Greenda Electronic Materials Co Ltd
SHG:603931
|
$769.76 Million |
|
Aktis Oncology, Inc. Common stock
NASDAQ:AKTS
|
$769.87 Million |
|
Hainan Shennong Technology Co Ltd
SHE:300189
|
$770.20 Million |
|
Latham Group Inc
NASDAQ:SWIM
|
$769.41 Million |
|
PLAYTIKA HOLDING DL-01
F:8II
|
$769.34 Million |
|
Shanghai Baosteel Packaging
SHG:601968
|
$769.15 Million |
|
Collins Foods Ltd
AU:CKF
|
$769.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hunan Jiudian Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,526,729,860 to 2,658,840,945, a change of 132,111,085 (5.2%).
- Net income of 472,818,049 contributed positively to equity growth.
- Dividend payments of 160,922,453 reduced retained earnings.
- Other comprehensive income decreased equity by 244,998,888.
- Other factors increased equity by 65,214,378.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥472.82 Million | +17.78% |
| Dividends Paid | CN¥160.92 Million | -6.05% |
| Other Comprehensive Income | CN¥-245.00 Million | -9.21% |
| Other Changes | CN¥65.21 Million | +2.45% |
| Total Change | CN¥- | 5.23% |
Book Value vs Market Value Analysis
This analysis compares Hunan Jiudian Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.98x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 18.86x to 1.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.56 | CN¥10.51 | x |
| 2014-12-31 | CN¥1.59 | CN¥10.51 | x |
| 2015-12-31 | CN¥1.12 | CN¥10.51 | x |
| 2016-12-31 | CN¥1.33 | CN¥10.51 | x |
| 2017-12-31 | CN¥2.48 | CN¥10.51 | x |
| 2018-12-31 | CN¥2.21 | CN¥10.51 | x |
| 2019-12-31 | CN¥2.32 | CN¥10.51 | x |
| 2020-12-31 | CN¥2.54 | CN¥10.51 | x |
| 2021-12-31 | CN¥3.35 | CN¥10.51 | x |
| 2022-12-31 | CN¥3.97 | CN¥10.51 | x |
| 2023-12-31 | CN¥5.72 | CN¥10.51 | x |
| 2024-12-31 | CN¥5.13 | CN¥10.51 | x |
| 2025-12-31 | CN¥5.32 | CN¥10.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hunan Jiudian Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.78%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.20%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 1.51x
- Recent ROE (17.78%) is above the historical average (15.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 20.61% | 15.02% | 0.96x | 1.43x | CN¥18.66 Million |
| 2014 | 19.65% | 15.47% | 0.99x | 1.28x | CN¥20.25 Million |
| 2015 | 17.54% | 15.37% | 0.91x | 1.25x | CN¥19.19 Million |
| 2016 | 16.86% | 14.49% | 0.95x | 1.23x | CN¥22.18 Million |
| 2017 | 10.39% | 12.83% | 0.69x | 1.17x | CN¥2.55 Million |
| 2018 | 10.02% | 8.98% | 0.85x | 1.31x | CN¥169.08K |
| 2019 | 7.23% | 5.96% | 0.86x | 1.41x | CN¥-21.12 Million |
| 2020 | 9.84% | 8.41% | 0.87x | 1.35x | CN¥-1.31 Million |
| 2021 | 18.58% | 12.55% | 0.93x | 1.59x | CN¥94.31 Million |
| 2022 | 17.37% | 11.59% | 1.01x | 1.48x | CN¥114.44 Million |
| 2023 | 18.66% | 13.68% | 0.94x | 1.46x | CN¥170.93 Million |
| 2024 | 20.28% | 17.48% | 0.87x | 1.33x | CN¥259.70 Million |
| 2025 | 17.78% | 15.20% | 0.77x | 1.51x | CN¥206.93 Million |
Industry Comparison
This section compares Hunan Jiudian Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,124,889,896
- Average return on equity (ROE) among peers: 7.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hunan Jiudian Pharmaceutical Co Ltd (300705) | CN¥2.75 Billion | 20.61% | 0.52x | $769.42 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $902.62 Million | 5.17% | 3.60x | $492.82 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.56 Billion | 7.90% | 1.45x | $363.79 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $366.91 Million | 9.97% | 0.26x | $4.71 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $14.91 Billion | 13.83% | 0.64x | $2.63 Billion |
| Wedge Industrial Co Ltd (000534) | $654.70 Million | 1.92% | 0.87x | $1.28 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $14.36 Billion |
| Hainan Haiyao Co Ltd (000566) | $317.39 Million | 7.74% | 0.74x | $766.98 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $268.54 Million | 1.60% | 1.47x | $273.68 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $889.22 Million | 5.34% | 2.43x | $935.44 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.35 Billion | 7.34% | 0.44x | $3.04 Billion |
About Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers chemical drug preparations, active pharmaceutical ingredients (APIs), pharmaceutical excipients, traditional Chinese medicine, health foods, and rehabilitation and wellness products. Its products portfolio includes loxoprofen sodium gel patches,… Read more